
CLAIMS:

1. A compound of Formula (II)



(II)

or a pharmaceutically acceptable salt thereof, wherein


R^1 is a phenyl or 6 membered heteroaryl optionally substituted with 1, 2, or 3 R^4;
X^1 is –C(H)= or –C(R^8)=;
X^4 is –C(H)=, -C(R^8)= or N;
each R^4 is independently halogen or -CN;
each R^B is independently C_{1-9} alkyl, C_{1-8} haloalkyl, or halogen;
each R^8 is independently H or halogen; and

n is 0, 1, 2, or 3.


2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein

R^1 is phenyl, substituted with halogen or -CN.

3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein


R^1 is , substituted with halogen or -CN.


4. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R^1 is





5. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R^8 is F or Cl.


6. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:
























































































































































































































































































































































































































.


7. The compound of claim 1 having the structure:



,

or a pharmaceutically acceptable salt thereof.


8. The compound of claim 1 having the structure:



,

or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1 having the structure:



,

or a pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

11. The pharmaceutical composition of claim 10 further comprising one or more additional therapeutic agents.

12. Use of a compound according to any one of claims 1-9, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating a glucagon-like peptide 1 receptor (GLP-1R) mediated disease or condition.

13. The use of claim 12, wherein the disease or condition comprises a liver disease.

14. The use of claim 13, wherein the disease or condition comprises liver fibrosis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver cirrhosis, compensated liver fibrosis, decompensated liver fibrosis, hepatocellular carcinoma, Primary Biliary Cirrhosis (PBC), or Primary Sclerosing Choleangitis (PSC).

15. The use of claim 14, wherein the disease or condition comprises non-alcoholic fatty liver disease (NAFLD).

16. The use of claim 14, wherein the disease or condition comprises non-alcoholic steatohepatitis (NASH).

17. The use of claim 12, wherein the disease or condition comprises a metabolic disease.

18. The use of claim 12, wherein the disease or condition comprises type 1 diabetes, type 2 diabetes, pre-diabetes, idiopathic type 1 diabetes, latent autoimmune diabetes, maturity onset diabetes of the young, early onset diabetes, malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin

resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease, diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, obesity, eating disorders, sleep apnea, weight gain, sugar craving, dyslipidemia, hyperinsulinemia, congestive heart failure, myocardial infarction, stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, post-prandial lipemia, metabolic acidosis, ketosis, arthritis, left ventricular hypertrophy, Parkinson's Disease, peripheral arterial disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, angina pectoris, premenstrual syndrome, thrombosis, atherosclerosis, impaired glucose metabolism, vascular restenosis, dementia, or Alzheimer's disease.

19. The use of any one of claims 12 to 18, wherein the compound or pharmaceutically acceptable salt thereof is to be administered in combination with an additional therapeutic agent.

20. The pharmaceutical composition of claim 11 or the use of claim 19, wherein the additional therapeutic agent comprises an anti-obesity agent including but not limited to peptide YY or an analogue thereof, a neuropeptide Y receptor type 2 (NPYR2) agonist, a NPYR1 agonist, an NPYR5 antagonist, a cannabinoid receptor type 1 (CB1 R) antagonist, a lipase inhibitor (*e.g.*, orlistat), a human proislet peptide (HIP), a melanocortin receptor 4 agonist (MC4R) (*e.g.*, setmelanotide), a melanin concentrating hormone receptor 1 antagonist, a farnesoid X receptor (FXR) agonist (*e.g.*, obeticholic acid), apoptotic signal-regulating kinase (ASK-1) inhibitor, zonisamide, phentermine (alone or in combination with topiramate), a norepinephrine/dopamine reuptake inhibitor (*e.g.*, buproprion), an opioid receptor antagonist (*e.g.*, naltrexone), a combination of norepinephrine/dopamine reuptake inhibitor and opioid receptor antagonist (*e.g.*, a combination of bupropion and naltrexone), a GDF-15 analog, sibutramine, a cholecystokinin agonist, amylin and analogues thereof (*e.g.*, pramlintide), leptin and analogues thereof (*e.g.*, metroleptin), a serotonergic agent (*e.g.*, lorcaserin), a methionine aminopeptidase 2 (MetAP2) inhibitor (*e.g.*, beloranib or ZGN-1061), phendimetrazine, diethylpropion, benzphetamine, an SGLT2 inhibitor (*e.g.*, empagliflozin, canagliflozin, dapagliflozin, ipragliflozin, tofogliflozin, sergliflozin etabonate, remogliflozin etabonate, or

ertugliflozin), an SGLTL1 inhibitor, a dual SGLT2/SGLT1 inhibitor, a fibroblast growth factor receptor (FGFR) modulator, an AMP-activated protein kinase (AMPK) activator, biotin, a MAS receptor modulator, or a glucagon receptor agonist (alone or in combination with another GLP-1 R agonist, *e.g.*, liraglutide, exenatide, dulaglutide, albiglutide, lixisenatide, or semaglutide), a peroxisome proliferator-activated receptor alpha (PPARα) agonist, fish oil, an acetyl-coA carboxylase (ACC) inhibitor, a TGFβ antagonist, GFRAL agonist, and/or a pharmaceutically acceptable salt thereof.